At the time of writing, Editas Medicine Inc [EDIT] stock is trading at $1.64, up 10.07%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EDIT shares have gain 9.33% over the last week, with a monthly amount glided 23.31%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on April 28, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $3. Previously, JP Morgan downgraded its rating to Underweight on December 16, 2024. On December 13, 2024, downgrade downgraded it’s rating to Hold. Stifel downgraded its rating to a Hold and decreased its price target to $3 on December 13, 2024. Chardan Capital Markets downgraded its rating to a Neutral. Wells Fargo downgraded its rating to Equal Weight for this stock on December 11, 2024, and downed its price target to $4. In a note dated November 25, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $13 to $1.
For the past year, the stock price of Editas Medicine Inc fluctuated between $0.91 and $6.22. Currently, Wall Street analysts expect the stock to reach $12.85 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $1.64 at the most recent close of the market. An investor can expect a potential return of 683.54% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
According to Editas Medicine Inc [NASDAQ:EDIT], the company’s sales were 35.84M for trailing twelve months, which represents an 310.40% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -5.91%, Pretax Profit Margin comes in at -8.06%, and Net Profit Margin reading is -8.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.95, Equity is -1.66 and Total Capital is -0.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.5.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Editas Medicine Inc [NASDAQ:EDIT] has a current ratio of 3.08. As well, the Quick Ratio is 3.08, while the Cash Ratio is 1.9. Considering the valuation of this stock, the price to sales ratio is 3.83, the price to book ratio is 2.20.
Transactions by insiders
Recent insider trading involved Lucera Erick, EVP, CHIEF FINANCIAL OFFICER, that happened on Mar 04 ’25 when 4109.0 shares were sold. CEO, O’Neill Gilmore Neil completed a deal on Mar 04 ’25 to sell 16632.0 shares. Meanwhile, EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold 2891.0 shares on Mar 04 ’25.
